Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genflow Biosciences Plc ( (GB:GENF) ) has issued an update.
Genflow Biosciences Plc, a UK-based longevity-focused biotechnology company listed in London and on OTCQB, is developing gene therapies such as its lead candidate GF-1002, which targets aging-related conditions and is under evaluation in an aged-dog study and in upcoming trials for MASH. The company aims to extend healthy lifespan and address the growing burden of age-related disease globally.
Genflow announced that shareholders approved all resolutions at its latest General Meeting, including authority for directors to allot securities and to disapply statutory pre-emption rights, both backed by strong voting majorities. The outcome gives the company greater flexibility to issue new equity, potentially supporting future financing and strategic initiatives as it advances its gene therapy pipeline in the competitive longevity biotech space.
The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.
Spark’s Take on GB:GENF Stock
According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.
To see Spark’s full report on GB:GENF stock, click here.
More about Genflow Biosciences Plc
Genflow Biosciences Plc is a UK-headquartered, European biotechnology company focused on longevity, with R&D facilities in Belgium and listings on LSE and OTCQB. Founded in 2020, it is pioneering gene therapies to decelerate aging, led by its GF-1002 candidate, a proprietary centenarian variant of the SIRT6 gene being tested in an aged-dog SLAB study and planned for clinical trials in MASH, a prevalent chronic liver disease lacking effective treatments.
Average Trading Volume: 2,372,272
Technical Sentiment Signal: Buy
Current Market Cap: £9.87M
Find detailed analytics on GENF stock on TipRanks’ Stock Analysis page.